Linezolid (PNU-100766) versus Vancomycin in the Treatment of Hospitalized Patients with Nosocomial Pneumonia: A Randomized, Double-Blind, Multicenter Study
Linezolid, the first oxazolidinone, is active against gram-positive bacteria, including multidrug-resistant strains. This multinational, randomized, double-blind, controlled trial compared the efficacy, safety, and tolerability of linezolid with vancomycin in the treatment of nosocomial pneumonia. A...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 2001-02, Vol.32 (3), p.402-412 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 412 |
|---|---|
| container_issue | 3 |
| container_start_page | 402 |
| container_title | Clinical infectious diseases |
| container_volume | 32 |
| creator | Rubinstein, Ethan Cammarata, Sue K. Oliphant, Thomas H. Wunderink, Richard G. |
| description | Linezolid, the first oxazolidinone, is active against gram-positive bacteria, including multidrug-resistant strains. This multinational, randomized, double-blind, controlled trial compared the efficacy, safety, and tolerability of linezolid with vancomycin in the treatment of nosocomial pneumonia. A total of 203 patients received intravenous linezolid, 600 mg twice daily, plus aztreonam, and 193 patients received vancomycin, 1 g intravenously twice daily, plus aztreonam for 7–21 days. Clinical and microbiological outcomes were evaluated at test of cure 12–28 days after treatment. Clinical cure rates (71 [66.4%] of 107 for linezolid vs. 62 [68.1%] of 91 for vancomycin) and microbiological success rates (36 [67.9%] of 53 vs. 28 [71.8%] of 39, respectively) for evaluable patients were equivalent between treatment groups. Eradication rates of methicillin-resistant Staphylococcus aureus and safety evaluations were similar between treatment groups. Resistance to either treatment was not detected. Linezolid is a well-tolerated, effective treatment for adults with gram-positive nosocomial pneumonia. |
| doi_str_mv | 10.1086/318486 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_17918489</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>4482490</jstor_id><oup_id>10.1086/318486</oup_id><sourcerecordid>4482490</sourcerecordid><originalsourceid>FETCH-LOGICAL-c451t-4184261534ad0b6c0e487c374c37c9dc691abfdbab939424f26562bfb363c5993</originalsourceid><addsrcrecordid>eNp1kW1rFDEQxxdRbK36CURSBFFwNdk8bOK7Wm1PuJ5nbUV8E7LZLE3Nbs4kq16_il_WHHucvhESMpn5zX-YmaJ4iOBLBDl7hREnnN0q9hHFdcmoQLezDSkvCcd8r7gX4zWECHFI7xZ7CKEaCsL3i99zO5gb72wLni0XlyWCsGbsOfhhQhwj-KwG7fu1tgPIJ10ZcBGMSr0ZEvAdmPm4skk5e2NasFTJZn8EP226AgsffU61yoHlYMbeD1a9BkfgXA1tdueEF-CtHxtnyjfODvl3NrpkdVYwAXxKY7u-X9zplIvmwfY9KC5P3l0cz8r5h9P3x0fzUhOKUkly6xXLfRPVwoZpaAivNa5Jvlq0mgmkmq5tVCOwIBXpKkZZ1XQNZlhTIfBB8XTSXQX_fTQxyd5GbZxTg_FjlKgWm-n-A-rgYwymk6tgexXWEkG5WYOc1pDBx1vFselN-xfbzj0DT7aAilq5LuQ527jjcj3GNjKHE-XH1f9LPZqY65h82FGE8IoImMPlFLYxmV-7sArfJKtxTeXsy1eJzyg_Pfl4Lhf4D1iZsPY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17918489</pqid></control><display><type>article</type><title>Linezolid (PNU-100766) versus Vancomycin in the Treatment of Hospitalized Patients with Nosocomial Pneumonia: A Randomized, Double-Blind, Multicenter Study</title><source>Jstor Complete Legacy</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Rubinstein, Ethan ; Cammarata, Sue K. ; Oliphant, Thomas H. ; Wunderink, Richard G.</creator><creatorcontrib>Rubinstein, Ethan ; Cammarata, Sue K. ; Oliphant, Thomas H. ; Wunderink, Richard G. ; Linezolid Nosocomial Pneumonia Study Group ; the Linezolid Nosocomial Pneumonia Study Group</creatorcontrib><description>Linezolid, the first oxazolidinone, is active against gram-positive bacteria, including multidrug-resistant strains. This multinational, randomized, double-blind, controlled trial compared the efficacy, safety, and tolerability of linezolid with vancomycin in the treatment of nosocomial pneumonia. A total of 203 patients received intravenous linezolid, 600 mg twice daily, plus aztreonam, and 193 patients received vancomycin, 1 g intravenously twice daily, plus aztreonam for 7–21 days. Clinical and microbiological outcomes were evaluated at test of cure 12–28 days after treatment. Clinical cure rates (71 [66.4%] of 107 for linezolid vs. 62 [68.1%] of 91 for vancomycin) and microbiological success rates (36 [67.9%] of 53 vs. 28 [71.8%] of 39, respectively) for evaluable patients were equivalent between treatment groups. Eradication rates of methicillin-resistant Staphylococcus aureus and safety evaluations were similar between treatment groups. Resistance to either treatment was not detected. Linezolid is a well-tolerated, effective treatment for adults with gram-positive nosocomial pneumonia.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1086/318486</identifier><identifier>PMID: 11170948</identifier><identifier>CODEN: CIDIEL</identifier><language>eng</language><publisher>Chicago, IL: The University of Chicago Press</publisher><subject>Acetamides - adverse effects ; Acetamides - therapeutic use ; Adult ; Aged ; Aged, 80 and over ; Anti-Bacterial Agents - adverse effects ; Anti-Bacterial Agents - therapeutic use ; Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antimicrobials ; aztreonam ; Aztreonam - therapeutic use ; Bacterial pneumonia ; Biological and medical sciences ; Cross Infection - drug therapy ; Double-Blind Method ; Drug Resistance, Microbial ; Drug Therapy, Combination ; Gram-Positive Bacteria - drug effects ; Hospitalization ; Humans ; Infections ; Infectious diseases ; Linezolid ; Major Article ; Male ; Medical sciences ; Medications ; Middle Aged ; Monobactams - therapeutic use ; Oxazolidinones ; Oxazolidinones - adverse effects ; Oxazolidinones - therapeutic use ; Pathogens ; Pharmacology. Drug treatments ; Pneumonia ; Pneumonia - drug therapy ; Safety ; Staphylococcal pneumonia ; State hospitals ; Time Factors ; Treatment Outcome ; vancomycin ; Vancomycin - adverse effects ; Vancomycin - therapeutic use</subject><ispartof>Clinical infectious diseases, 2001-02, Vol.32 (3), p.402-412</ispartof><rights>Copyright 2001 The Infectious Diseases Society of America</rights><rights>2001 by the Infectious Diseases Society of America 2001</rights><rights>2001 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c451t-4184261534ad0b6c0e487c374c37c9dc691abfdbab939424f26562bfb363c5993</citedby><cites>FETCH-LOGICAL-c451t-4184261534ad0b6c0e487c374c37c9dc691abfdbab939424f26562bfb363c5993</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/4482490$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/4482490$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,776,780,799,27901,27902,57992,58225</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=918666$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11170948$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rubinstein, Ethan</creatorcontrib><creatorcontrib>Cammarata, Sue K.</creatorcontrib><creatorcontrib>Oliphant, Thomas H.</creatorcontrib><creatorcontrib>Wunderink, Richard G.</creatorcontrib><creatorcontrib>Linezolid Nosocomial Pneumonia Study Group</creatorcontrib><creatorcontrib>the Linezolid Nosocomial Pneumonia Study Group</creatorcontrib><title>Linezolid (PNU-100766) versus Vancomycin in the Treatment of Hospitalized Patients with Nosocomial Pneumonia: A Randomized, Double-Blind, Multicenter Study</title><title>Clinical infectious diseases</title><addtitle>Clinical Infectious Diseases</addtitle><addtitle>Clinical Infectious Diseases</addtitle><description>Linezolid, the first oxazolidinone, is active against gram-positive bacteria, including multidrug-resistant strains. This multinational, randomized, double-blind, controlled trial compared the efficacy, safety, and tolerability of linezolid with vancomycin in the treatment of nosocomial pneumonia. A total of 203 patients received intravenous linezolid, 600 mg twice daily, plus aztreonam, and 193 patients received vancomycin, 1 g intravenously twice daily, plus aztreonam for 7–21 days. Clinical and microbiological outcomes were evaluated at test of cure 12–28 days after treatment. Clinical cure rates (71 [66.4%] of 107 for linezolid vs. 62 [68.1%] of 91 for vancomycin) and microbiological success rates (36 [67.9%] of 53 vs. 28 [71.8%] of 39, respectively) for evaluable patients were equivalent between treatment groups. Eradication rates of methicillin-resistant Staphylococcus aureus and safety evaluations were similar between treatment groups. Resistance to either treatment was not detected. Linezolid is a well-tolerated, effective treatment for adults with gram-positive nosocomial pneumonia.</description><subject>Acetamides - adverse effects</subject><subject>Acetamides - therapeutic use</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anti-Bacterial Agents - adverse effects</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antimicrobials</subject><subject>aztreonam</subject><subject>Aztreonam - therapeutic use</subject><subject>Bacterial pneumonia</subject><subject>Biological and medical sciences</subject><subject>Cross Infection - drug therapy</subject><subject>Double-Blind Method</subject><subject>Drug Resistance, Microbial</subject><subject>Drug Therapy, Combination</subject><subject>Gram-Positive Bacteria - drug effects</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Linezolid</subject><subject>Major Article</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medications</subject><subject>Middle Aged</subject><subject>Monobactams - therapeutic use</subject><subject>Oxazolidinones</subject><subject>Oxazolidinones - adverse effects</subject><subject>Oxazolidinones - therapeutic use</subject><subject>Pathogens</subject><subject>Pharmacology. Drug treatments</subject><subject>Pneumonia</subject><subject>Pneumonia - drug therapy</subject><subject>Safety</subject><subject>Staphylococcal pneumonia</subject><subject>State hospitals</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>vancomycin</subject><subject>Vancomycin - adverse effects</subject><subject>Vancomycin - therapeutic use</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kW1rFDEQxxdRbK36CURSBFFwNdk8bOK7Wm1PuJ5nbUV8E7LZLE3Nbs4kq16_il_WHHucvhESMpn5zX-YmaJ4iOBLBDl7hREnnN0q9hHFdcmoQLezDSkvCcd8r7gX4zWECHFI7xZ7CKEaCsL3i99zO5gb72wLni0XlyWCsGbsOfhhQhwj-KwG7fu1tgPIJ10ZcBGMSr0ZEvAdmPm4skk5e2NasFTJZn8EP226AgsffU61yoHlYMbeD1a9BkfgXA1tdueEF-CtHxtnyjfODvl3NrpkdVYwAXxKY7u-X9zplIvmwfY9KC5P3l0cz8r5h9P3x0fzUhOKUkly6xXLfRPVwoZpaAivNa5Jvlq0mgmkmq5tVCOwIBXpKkZZ1XQNZlhTIfBB8XTSXQX_fTQxyd5GbZxTg_FjlKgWm-n-A-rgYwymk6tgexXWEkG5WYOc1pDBx1vFselN-xfbzj0DT7aAilq5LuQ527jjcj3GNjKHE-XH1f9LPZqY65h82FGE8IoImMPlFLYxmV-7sArfJKtxTeXsy1eJzyg_Pfl4Lhf4D1iZsPY</recordid><startdate>20010201</startdate><enddate>20010201</enddate><creator>Rubinstein, Ethan</creator><creator>Cammarata, Sue K.</creator><creator>Oliphant, Thomas H.</creator><creator>Wunderink, Richard G.</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>C1K</scope></search><sort><creationdate>20010201</creationdate><title>Linezolid (PNU-100766) versus Vancomycin in the Treatment of Hospitalized Patients with Nosocomial Pneumonia: A Randomized, Double-Blind, Multicenter Study</title><author>Rubinstein, Ethan ; Cammarata, Sue K. ; Oliphant, Thomas H. ; Wunderink, Richard G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c451t-4184261534ad0b6c0e487c374c37c9dc691abfdbab939424f26562bfb363c5993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Acetamides - adverse effects</topic><topic>Acetamides - therapeutic use</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anti-Bacterial Agents - adverse effects</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antimicrobials</topic><topic>aztreonam</topic><topic>Aztreonam - therapeutic use</topic><topic>Bacterial pneumonia</topic><topic>Biological and medical sciences</topic><topic>Cross Infection - drug therapy</topic><topic>Double-Blind Method</topic><topic>Drug Resistance, Microbial</topic><topic>Drug Therapy, Combination</topic><topic>Gram-Positive Bacteria - drug effects</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Linezolid</topic><topic>Major Article</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medications</topic><topic>Middle Aged</topic><topic>Monobactams - therapeutic use</topic><topic>Oxazolidinones</topic><topic>Oxazolidinones - adverse effects</topic><topic>Oxazolidinones - therapeutic use</topic><topic>Pathogens</topic><topic>Pharmacology. Drug treatments</topic><topic>Pneumonia</topic><topic>Pneumonia - drug therapy</topic><topic>Safety</topic><topic>Staphylococcal pneumonia</topic><topic>State hospitals</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>vancomycin</topic><topic>Vancomycin - adverse effects</topic><topic>Vancomycin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rubinstein, Ethan</creatorcontrib><creatorcontrib>Cammarata, Sue K.</creatorcontrib><creatorcontrib>Oliphant, Thomas H.</creatorcontrib><creatorcontrib>Wunderink, Richard G.</creatorcontrib><creatorcontrib>Linezolid Nosocomial Pneumonia Study Group</creatorcontrib><creatorcontrib>the Linezolid Nosocomial Pneumonia Study Group</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rubinstein, Ethan</au><au>Cammarata, Sue K.</au><au>Oliphant, Thomas H.</au><au>Wunderink, Richard G.</au><aucorp>Linezolid Nosocomial Pneumonia Study Group</aucorp><aucorp>the Linezolid Nosocomial Pneumonia Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Linezolid (PNU-100766) versus Vancomycin in the Treatment of Hospitalized Patients with Nosocomial Pneumonia: A Randomized, Double-Blind, Multicenter Study</atitle><jtitle>Clinical infectious diseases</jtitle><stitle>Clinical Infectious Diseases</stitle><addtitle>Clinical Infectious Diseases</addtitle><date>2001-02-01</date><risdate>2001</risdate><volume>32</volume><issue>3</issue><spage>402</spage><epage>412</epage><pages>402-412</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><coden>CIDIEL</coden><abstract>Linezolid, the first oxazolidinone, is active against gram-positive bacteria, including multidrug-resistant strains. This multinational, randomized, double-blind, controlled trial compared the efficacy, safety, and tolerability of linezolid with vancomycin in the treatment of nosocomial pneumonia. A total of 203 patients received intravenous linezolid, 600 mg twice daily, plus aztreonam, and 193 patients received vancomycin, 1 g intravenously twice daily, plus aztreonam for 7–21 days. Clinical and microbiological outcomes were evaluated at test of cure 12–28 days after treatment. Clinical cure rates (71 [66.4%] of 107 for linezolid vs. 62 [68.1%] of 91 for vancomycin) and microbiological success rates (36 [67.9%] of 53 vs. 28 [71.8%] of 39, respectively) for evaluable patients were equivalent between treatment groups. Eradication rates of methicillin-resistant Staphylococcus aureus and safety evaluations were similar between treatment groups. Resistance to either treatment was not detected. Linezolid is a well-tolerated, effective treatment for adults with gram-positive nosocomial pneumonia.</abstract><cop>Chicago, IL</cop><pub>The University of Chicago Press</pub><pmid>11170948</pmid><doi>10.1086/318486</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 2001-02, Vol.32 (3), p.402-412 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_17918489 |
| source | Jstor Complete Legacy; Oxford University Press Journals All Titles (1996-Current); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Acetamides - adverse effects Acetamides - therapeutic use Adult Aged Aged, 80 and over Anti-Bacterial Agents - adverse effects Anti-Bacterial Agents - therapeutic use Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Antimicrobials aztreonam Aztreonam - therapeutic use Bacterial pneumonia Biological and medical sciences Cross Infection - drug therapy Double-Blind Method Drug Resistance, Microbial Drug Therapy, Combination Gram-Positive Bacteria - drug effects Hospitalization Humans Infections Infectious diseases Linezolid Major Article Male Medical sciences Medications Middle Aged Monobactams - therapeutic use Oxazolidinones Oxazolidinones - adverse effects Oxazolidinones - therapeutic use Pathogens Pharmacology. Drug treatments Pneumonia Pneumonia - drug therapy Safety Staphylococcal pneumonia State hospitals Time Factors Treatment Outcome vancomycin Vancomycin - adverse effects Vancomycin - therapeutic use |
| title | Linezolid (PNU-100766) versus Vancomycin in the Treatment of Hospitalized Patients with Nosocomial Pneumonia: A Randomized, Double-Blind, Multicenter Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T03%3A11%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Linezolid%20(PNU-100766)%20versus%20Vancomycin%20in%20the%20Treatment%20of%20Hospitalized%20Patients%20with%20Nosocomial%20Pneumonia:%20A%20Randomized,%20Double-Blind,%20Multicenter%20Study&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Rubinstein,%20Ethan&rft.aucorp=Linezolid%20Nosocomial%20Pneumonia%20Study%20Group&rft.date=2001-02-01&rft.volume=32&rft.issue=3&rft.spage=402&rft.epage=412&rft.pages=402-412&rft.issn=1058-4838&rft.eissn=1537-6591&rft.coden=CIDIEL&rft_id=info:doi/10.1086/318486&rft_dat=%3Cjstor_proqu%3E4482490%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17918489&rft_id=info:pmid/11170948&rft_jstor_id=4482490&rft_oup_id=10.1086/318486&rfr_iscdi=true |